Asahi Kasei Pharma Corp., a Japan-based drugmaker looking to license, acquire assets, initiate strategic alliances or R&D collaboration, in the therapeutic areas of musculoskeletal disorders including pain management, autoimmune disorders, critical care and orphan diseases.
